ST6GAL1 and prostate carcinoma: Scott et al. identified an important role for ST6GAL1 and α2,6 sialylated N-glycans in the progression of prostate cancer, and highlighted the opportunity to inhibit abnormal sialylation for the development of new prostate cancer [25].